We are live on
!
Find out more
ACP
Acuta Capital Partners Portfolio holdings
AUM
$143M
1-Year Est. Return
773.18%
This Fund
S&P 500
This Quarter
Est. Return
+56.41%
1 Year Est. Return
+773.18%
3 Year Est. Return
+7,269.42%
5 Year Est. Return
+14,284.66%
10 Year Est. Return
+1,769,765.59%
AUM
$281M
AUM Growth
+$70.9M
(+34%)
Cap. Flow
-$140K
Cap. Flow
% of AUM
-0.05%
Top 10 Holdings %
Top 10 Hldgs %
63.76%
Holding
43
New
10
Increased
13
Reduced
5
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Axsome Therapeutics
AXSM
|
+$8.77M |
| 2 |
Milestone Pharmaceuticals
MIST
|
+$7.16M |
| 3 |
Arrowhead Research
ARWR
|
+$6.83M |
| 4 |
ATNX
Athenex, Inc. Common Stock
ATNX
|
+$6.55M |
| 5 |
Aurinia Pharmaceuticals
AUPH
|
+$5.96M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CASM
CAS Medical Systems, Inc.
CASM
|
+$12.8M |
| 2 |
Assembly Biosciences
ASMB
|
+$9.54M |
| 3 |
DERM
Dermira, Inc.
DERM
|
+$8.63M |
| 4 |
Iovance Biotherapeutics
IOVA
|
+$7.79M |
| 5 |
CBAY
Cymabay Therapeutics
CBAY
|
+$6.87M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.2% |
| 2 | Miscellaneous | 7.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Iovance Biotherapeutics
IOVA
$4.58B
| $59.5M | 21.16% |
2,426,701
-517,500
| -18% | -$7.79M |
|
2
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.7B
| $17.5M | 6.24% |
+200,000
| New | +$17.1M |
|
|
KDMN
3
DELISTED
Kadmon Holdings, Inc.
KDMN
| $15.7M | 5.58% |
7,617,500
-17,500
| -0.2% | -$39K |
|
|
ADVM
4
DELISTED
Adverum Biotechnologies
ADVM
| $14.1M | 5.03% |
119,000
+27,100
| +29% | +$2.24M |
|
5
Veracyte
VCYT
$3.26B
| $13.7M | 4.88% |
481,500
+100,000
| +26% | +$2.5M |
|
|
6
Arrowhead Research
ARWR
$9.55B
| $12.7M | 4.51% |
478,500
+311,000
| +186% | +$6.83M |
|
7
Arvinas
ARVN
$541M
| $12.1M | 4.31% |
551,000
+237,000
| +75% | +$4.98M |
|
8
argenx
ARGX
$62.7B
| $11.5M | 4.08% |
81,000
+17,500
| +28% | +$2.22M |
|
|
9
Axsome Therapeutics
AXSM
$11.2B
| $11.3M | 4.01% |
+437,500
| New | +$8.77M |
|
|
BHVN
10
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $11.2M | 3.97% |
255,000
+49,000
| +24% | +$2.76M |
|
11
Insmed
INSM
$26.9B
| $11.1M | 3.96% |
435,500
+65,500
| +18% | +$1.82M |
|
|
12
Milestone Pharmaceuticals
MIST
$115M
| $9.42M | 3.35% |
+347,000
| New | +$7.16M |
|
|
ATNX
13
DELISTED
Athenex, Inc. Common Stock
ATNX
| $9.36M | 3.33% |
+23,625
| New | +$6.55M |
|
14
Protagonist Therapeutics
PTGX
$9.2B
| $8.13M | 2.89% |
671,500
+334,000
| +99% | +$3.69M |
|
|
VRAY
15
DELISTED
ViewRay, Inc.
VRAY
| $7.42M | 2.64% |
842,500
+27,500
| +3% | +$223K |
|
16
Xenon Pharmaceuticals
XENE
$4.12B
| $6.92M | 2.46% |
701,500
+149,000
| +27% | +$1.43M |
|
|
MRTX
17
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $6.44M | 2.29% |
62,500
+21,500
| +52% | +$1.67M |
|
|
18
Aurinia Pharmaceuticals
AUPH
$2.25B
| $6.15M | 2.19% |
+935,000
| New | +$5.96M |
|
|
DRNA
19
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $6.06M | 2.15% |
384,500
+55,675
| +17% | +$757K |
|
20
IRIDEX
IRIX
$11.2M
| $5.33M | 1.89% |
1,171,300
-3,200
| -0.3% | -$15.6K |
|
|
KALV
21
DELISTED
KalVista Pharmaceuticals
KALV
| $4.72M | 1.68% |
213,000
+7,500
| +4% | +$176K |
|
|
FOLD
22
DELISTED
Amicus Therapeutics
FOLD
| $4.37M | 1.55% |
+350,000
| New | +$4.44M |
|
23
CRISPR Therapeutics
CRSP
$5.64B
| $3.72M | 1.32% |
+79,000
| New | +$3.16M |
|
|
IMMU
24
DELISTED
Immunomedics Inc
IMMU
| $3.12M | 1.11% |
225,000
-275,000
| -55% | -$4.14M |
|
|
BHVN
25
CALL
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $2.19M | 0.78% |
50,000
| – | – |
|
Similar funds
FPC
WWM
AVA
BOM
PWM
FF
JPT
BJF
Acuta Capital Partners's Q2 2019 Portfolio in Review
As of Q2 2019, Acuta Capital Partners held 43 positions worth $281M, up 34% from $210M the previous quarter. Its ten largest holdings account for 64% of the portfolio.
Acuta Capital Partners's Q2 2019 filing shows 10 new, 13 increased, 5 reduced and 13 closed positions. Its largest new stake was Axsome Therapeutics: 437,500 shares worth $11.3M. The largest sale was CAS Medical Systems, Inc., an estimated $12.8M.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 99% a quarter earlier, followed by Miscellaneous.
- Acuta Capital Partners's largest Q2 2019 buy was Axsome Therapeutics: 437,500 shares worth $11.3M.
- Acuta Capital Partners added most to Arrowhead Research in Q2 2019, an estimated $6.83M increase.
- Acuta Capital Partners's biggest Q2 2019 reduction was Assembly Biosciences, cutting an estimated $9.54M.
- Acuta Capital Partners fully exited CAS Medical Systems, Inc. in Q2 2019, selling an estimated $12.8M.
- Acuta Capital Partners's ten largest holdings make up 64% of its $281M portfolio in Q2 2019.
- Acuta Capital Partners opened 10 new positions and closed 13 in Q2 2019.
- Acuta Capital Partners's portfolio value rose 34% quarter-over-quarter to $281M.
Based on Acuta Capital Partners's 13F filing for Q2 2019, filed 14 Aug 2019.